Review

Digital Biomarkers of Gait and Balance in Diabetic Foot, Measurable by Wearable Inertial Measurement Units: A Mini Review

Gu Eon Kang 1,2,*, Angeloh Stout 1, Ke’ Vaughn Waldon 1, Seungmin Kang 1, Amanda L. Killeen 2, Peter A. Crisologo 2, Michael Siah 3, Daniel Jupiter 4, Bijan Najafi 5, Ashkan Vaziri 6 and Lawrence A. Lavery 2

1 Department of Bioengineering, Erik Jonsson School of Engineering & Computer Science, The University of Texas at Dallas, Richardson, TX 75080, USA
2 Department of Plastic Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
3 Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
4 Department of Biostatistics and Data Science, Department of Orthopaedic Surgery and Rehabilitation, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA
5 Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
6 BioSensics LLC, Newton, MA 02458, USA
* Correspondence: gueon.kang2@utdallas.edu; Tel.: +1-972-883-5153

Abstract: People with diabetic foot frequently exhibit gait and balance dysfunction. Recent advances in wearable inertial measurement units (IMUs) enable to assess some of the gait and balance dysfunction associated with diabetic foot (i.e., digital biomarkers of gait and balance). However, there is no review to inform digital biomarkers of gait and balance dysfunction related to diabetic foot, measurable by wearable IMUs (e.g., what gait and balance parameters can wearable IMUs collect? Are the measurements repeatable?). Accordingly, we conducted a web-based, mini review using PubMed. Our search was limited to human subjects and English-written papers published in peer-reviewed journals. We identified 20 papers in this mini review. We found preliminary evidence of digital biomarkers of gait and balance dysfunction in people with diabetic foot, such as slow gait speed, large gait variability, unstable gait initiation, and large body sway. However, due to heterogeneities in included papers in terms of study design, movement tasks, and small sample size, more studies are recommended to confirm this preliminary evidence. Additionally, based on our mini review, we recommend establishing appropriate strategies to successfully incorporate wearable-based assessment into clinical practice for diabetic foot care.

Keywords: diabetic foot; diabetic neuropathies; peripheral arterial disease; foot ulcer; gait; walking; postural balance; wearable electronic devices; inertial measurement unit; digital technology

1. Introduction

The global epidemic of diabetes imposes significant burdens on healthcare systems [1]. The International Diabetes Federation estimated that in the year 2021, 537 million people were living with diabetes worldwide, and that this number would increase to 643 million by the year 2030 and 783 million by the year 2045 [2]. Diabetes is a cause of 6.7 million deaths worldwide [2]. Medical expenditures for diabetes are enormous: more than $200 billion in the USA alone and nearly $1 trillion worldwide [2,3].

Diabetes comprises a group of disorders that results in high blood-glucose levels, namely hyperglycemia, caused by deficits in insulin response [4]. There are two main types of diabetes: type 1 diabetes, also known as insulin-dependent diabetes, and type 2 diabetes, characterized by insulin-resistance [5,6]. More than 90% of people with diabetes have type 2 diabetes [6]. If poorly managed, diabetes causes a number of complications.

Diabetic foot, defined as “infection, ulceration or destruction of tissues of the foot associated with diabetic neuropathy or peripheral artery disease in the lower limb of
a person with diabetes” [7], is one of the most common and devastating complications of diabetes, which affects 2–6% of people with diabetes annually [8,9]. Diabetic foot accounts for more than 100,000 lower-extremity amputations in the USA and more than 1,000,000 lower-extremity amputations worldwide each year [10,11]. Remarkably, lower-extremity amputation is more fearful than death for people with diabetic foot [12].

Although diabetic foot is generally a consequence of multiple factors, common causal factors are sensory neuropathy causing sensory loss, motor neuropathy causing biomechanical abnormalities, autonomic neuropathy causing dry skin, and peripheral arterial disease causing claudication, rest pain, and tissue loss in the lower-extremity [13]. All these factors inherently limit gait and balance [14].

Gait and balance dysfunction has significant negative impacts on survival and quality of life of people with diabetic foot [15]. For example, the risk of fall and likelihood to be injured from a fall in people with diabetic foot is 23 and 15 times greater, respectively, than in people without diabetic foot [16]. Gait and balance dysfunction in people with diabetic foot is associated with an onset or progression of fear of falling, and restricts normal daily activities [17–19]. Furthermore, gait and balance dysfunction alters kinematics and kinetics, such as excessive plantar pressure and shear stress, and may contribute to the development of a foot ulcer or leads to deterioration of an already developed foot ulcer [20,21]. Thus, assessing gait and balance with valid and effective tools has been a critically important aspect of the management of diabetic foot.

Traditionally, visual observation in clinical settings or 3D-optoelectronic-motion capture systems in laboratory settings have been popularly utilized to assess gait and balance in people with diabetic foot. However, visual observation relies on clinicians’ experiences and is limited to gait speed, and 3D-optoelectronic-motion capture systems are expensive, time-consuming, and may not be suitable for translational research [22,23]. Instrumented walkways are another popular method; however, they are also expensive and limited to a relatively short distance (four to eight meters).

Wearable inertial measurement units (IMUs) are a viable option that can address limitations of the popular methods. Wearable IMUs, typically composed of an accelerometer and a gyroscope, have shown to provide repeatable and valid data in gait and balance assessment across clinical settings [24,25]. For example, Schwenk and colleagues used five IMUs attached on the shins, thighs, and lower back, and reported spatiotemporal parameters during gait and balance parameters during quiet standing tasks [26]. Furthermore, recent technical advances enabled wearable IMUs to assess gait and balance outside traditional gait laboratories in diabetic foot [27].

Nevertheless, we found no published reviews regarding these aspects. Accordingly, we aimed to summarize up-to-date findings regarding gait and balance assessment in people with diabetic foot using wearable IMUs. In particular, because gait and balance assessment using wearable IMUs is an emerging area of research, which has been studied only in recent years, and our topics (i.e., diabetic foot, wearable IMUs, gait and balance) are specific rather than broad, we conducted a mini review in this study. The primary focuses of our mini review were parameters of gait and balance measurable by wearable IMUs in people with diabetic foot, and repeatability of such parameters. Additionally, based on our mini review, we aimed to discuss limitations from previous papers and suggest areas of future research in gait and balance assessment in people with diabetic foot using IMUs.

2. Materials and Methods

Since this study was a mini review, we performed a web-based, electronic search using one database, PubMed (which covers a significant number of citations [≥34 million] for biomedical research papers), for papers published before 9 August 2022. The following terms were used for PubMed search: “diabetic neuropathies”, “diabetic foot”, “peripheral arterial disease”, “foot ulcer”, “gait”, “walking”, and “postural balance”. The full search query is described in Table 1.
Table 1. PubMed search query.

| Concept          | Search Query                                                                 |
|------------------|------------------------------------------------------------------------------|
| Diabetic Foot    | “Diabetic Neuropathies” [MeSH Terms] OR “Diabetic Foot” [MeSH Terms] OR “Foot Ulcer” [MeSH Terms] OR “Peripheral Arterial Disease” [MeSH Terms]) |
| AND              |                                                                             |
| Gait and Balance | “Gait” [MeSH Terms] OR “Walking” [MeSH Terms] OR “Postural Balance” [MeSH Terms] |

Our inclusion criteria were English-written papers that assessed gait and balance performance using IMUs in people with diabetic foot. If a paper utilized either an accelerometer or a gyroscope, we included the paper. Additional inclusion criteria were papers reported outcomes related to kinematic variables during gait and/or quiet standing, such as spatiotemporal parameters during gait or center-of-mass displacement during quiet standing. An experienced reviewer (G.E.K.) conducted screening of the searched papers based on titles and abstracts. This reviewer had sufficient experiences in such tasks and published multiple reviews previously [28,29].

Exclusion criteria were review papers, editorial comments, conference abstracts, and letters from the final paper selection. We limited our search of papers to human-subject studies, and thus, excluded animal studies. Additionally, if a paper reported a validity of IMUs in comparison to another motion-analysis system or subjective reports within one group, we excluded the paper. Furthermore, because the focus of this review is diabetic foot, if a paper included people with diabetes, assessed gait, and balance performance using IMUs, but did not specify the presence or a diagnosis of foot complications in the people of diabetes, the paper was excluded from final selection.

3. Results

3.1. Search Results

The flow diagram for paper selection is shown in Figure 1. A total of 986 papers were identified through PubMed. After screening titles and abstracts, 964 papers were excluded because they did not meet our inclusion and exclusion criteria, described in the previous section. After evaluating eligibility of the remaining 22 articles, two more papers were excluded based on full-text review because they were validation studies comparing two different measurements. Consequently, 20 papers were included in the current review [30–49].
3.2. Study Characteristics

We summarized the findings from the final 20 papers in Table 2. All included papers were published between 2004 and 2021: a total of thirteen studies were conducted in the USA, three studies in Switzerland, one study in Australia, one study in the UK, one study in China, and one study jointly conducted in the USA and Qatar.

Table 2. Summary of included papers. A list of abbreviations was added at the bottom of this table.

| Study Title Country | Study Design | Tasks | Sensor Type (Manufacturer) | Placement | Sampling Frequency | Key Measures | Findings |
|---------------------|--------------|-------|---------------------------|------------|--------------------|--------------|---------|
| Menz et al., 2004 [30] Walking stability and sensorimotor function in older people with diabetic peripheral neuropathy Australia | Observational DPN | Gait 20 m Two surface conditions • Level • Irregular | 3D Accelerometer (NA) | n = 2 | Duration of DM (years) = 12.3 ± 8.4 | Gait speed, cadence, step length, and smoothness on both surfaces in DPN vs. HC | ↓ Gait speed, cadence, step length, and smoothness on both surfaces in DPN vs. HC | † Step time variability on irregular surface in DPN vs. HC |
| | | | | | Head (n = 1) Sacrum (n = 1) Frequency not reported | Step time variability Smoothness (harmonic ratio) | | | |
Table 2. Cont.

| Study Title                                                                 | Study Design                                                                 | Participants                                                                 | Tasks                                 | Sensor Type (Manufacturer) | Placement | Sampling Frequency | Key Measures                                                                 | Findings                                                                 |
|---------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------|---------------------------|-----------|-------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Gait alterations of diabetic patients on different surfaces                | Observational                                                                | DPN                                                                          | n = 15 (sex ratio not reported)      | IMU (BioAGM, Lausanne, Switzerland) | VPT (Scale) | = 3.3 ± 1.3       | Gait speed, cadence, and stride length in DPN vs. HC, but not DPN vs. DM  |                                                                          |
|                                                                           | Country                                                                       | Switzerland                                                                  | Age (years) = 61.29 ± 6.52          |                           | Frequency = 200 Hz |                      | Gait cycle time, and stride time variability on all surfaces in DPN vs. HC, but not DPN vs. DM |                                                                          |
|                                                                           |                                                                                                   | Weight (kg) = 86.94 ± 1.93                                                   | Duration of DM (years) = 8.83 ± 4.60 |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Blood sugar level not reported VPT (Scale) = 2.63 ± 1.58                     |                       |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Blood sugar level not reported                                               |                       |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Gait distance not reported                                                    |                       |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Three surface conditions                                                     |                       |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Tar                                                                        |                       |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Grass                                                                       |                       |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Stones                                                                      |                       |                           |                       |                   |                                                                            |                                                                          |
|                                                                           | Interventional (RCT): IG (Exercise intervention 60 min per session; two sessions per week, 12 weeks) | DPN                                                                          | n = 35 (sex ratio not reported)     | Gyroscope (NA)            | VPT (Scale) | = 3.2 ± 1.3       | Gait speed, cadence, and stride length in IG at 12-week and 6-month vs. baseline on both surfaces |                                                                          |
|                                                                           | Country                                                                       | Switzerland                                                                  | Age (years) = 63.0 ± 6.0           |                           | Frequency = 200 Hz |                      | Gait cycle time, and stride time variability on all surfaces in IG at 12-week and 6-month vs. baseline on both surfaces |                                                                          |
|                                                                           |                                                                                                   | BMI (kg/m²) = 30.5 ± 6.0                                                     | Disease duration not reported      |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Blood sugar level not reported VPT (Scale) = 3.2 ± 1.3                      | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Gait distance not reported                                                    | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Two surface conditions                                                      | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Tar                                                                         | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Cobblestone                                                                 | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Grass                                                                       | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Stones                                                                      | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           | Interventional (RCT): IG (Exercise intervention 60 min per session; two sessions per week, 12 weeks) | DPN                                                                          | n = 36 (sex ratio not reported)    | Gyroscope (NA)            | VPT (Scale) | = 3.3 ± 1.3       | Gait speed, cadence, and stride length in IG at 12-week and 6-month vs. baseline on both surfaces |                                                                          |
|                                                                           | Country                                                                       | Switzerland                                                                  | Age (years) = 64.0 ± 8.9           |                           | Frequency = 200 Hz |                      | Gait cycle time, and stride time variability on all surfaces in IG at 12-week and 6-month vs. baseline on both surfaces |                                                                          |
|                                                                           |                                                                                                   | BMI (kg/m²) = 31.5 ± 5.3                                                     | Disease duration not reported      |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Blood sugar level not reported VPT (Scale) = 3.3 ± 1.3                      | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Gait distance not reported                                                    | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Two surface conditions                                                      | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Tar                                                                         | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Cobblestone                                                                 | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Grass                                                                       | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | • Stones                                                                      | Blood sugar level not reported     |                           |                       |                   |                                                                            |                                                                          |
|                                                                           | Observational                                                                | DPN with diabetic foot risk classification: Grade 1 (n = 8)                 | Gait 20 m                           | IMU (BioAGM, Lausanne, Switzerland) | VPT (Scale) | = 3.3 ± 1.3       | Gait speed and stride length in ankle-high RCW and knee-high RCW vs. standard athletic shoe |                                                                            |
|                                                                           | Country                                                                       | Grade 3 (n = 1)                                                             |                                  |                           | Frequency = 200 Hz |                      | Stride time, double support, and gait speed variability in ankle-high RCW and knee-high RCW vs. standard athletic shoe |                                                                            |
|                                                                           |                                                                                                   | Grade 4 (n = 2)                                                             | Four shoe conditions               |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Age (years) = 51.4 ± 10.0                                                    | • Ankle-high RCW                   |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | BMI (kg/m²) = 33.9 ± 7.3                                                    | • Knee-high RCW                    |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Duration of DM (years) = 14.5 ± 9                                            | • Shoe RCW                         |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Blood sugar level not reported VPT value not provided                      | • Standard athletic shoe           |                           |                       |                   |                                                                            |                                                                          |
|                                                                           |                                                                                                   | Gait distance not reported                                                    | • Standard athletic shoe           |                           |                       |                   |                                                                            |                                                                          |
| Study Title | Study Design | Participants | Tasks | Sensor Type (Manufacturer) | Placement | Sampling Frequency | Key Measures | Findings |
|-------------|--------------|---------------|-------|----------------------------|-----------|-------------------|-------------|---------|
| Najafi et al., 2013a | Observational | DPN | Gait | Four conditions (two-distance × two footwear) | IMU (BioSensics, Newton, MA, USA) | n = 5 | Gait initiation steps | All variables were similar between DPN and HC in the short-distance condition regardless of footwear conditions |
| | | n = 12 (8 men; 4 women) Age (years) = 60 ± 12 BMI (kg/m²) = 32.3 ± 6.4 Duration of DM (years) = 10 ± 13 Blood sugar level not reported VPT (Volts; right foot) = 56 ± 25 | Gait initiation speed Gait speed Stride length Stride time Double limb support Gait speed variability CoM sway | | | |
| | | VPT (Volts; left foot) = 61 ± 29 HC | | | | | |
| | | n = 8 (6 men; 2 women) Age (years) = 60 ± 6 BMI (kg/m²) = 27.0 ± 3.2 VPT (Volts; right foot) = 19 ± 4 | | | | | |
| | | VPT (Volts; left foot) = 20 ± 3 | | | | | |
| Najafi et al., 2013b | Interventional (RCT) | IG (Electrical plantar stimulation; 30 min per treatment; 5 treatments per week; 6 weeks) | Quiet standing | Two conditions | IMU (BioSensics, Newton, MA, USA) | n = 2 | CoM sway area | All variables were similar between Ig and CG at baseline. |
| | | n = 25 (sex ratio not reported) Age (years) = 61.6 ± 8.3 BMI not reported Disease duration not reported HbA1c (%) = 7.6 ± 1.6 VPT (Volts) = 46.8 ± 23 | CoM sway area Time points: Baseline 2-week 4-week 6-week 6-month | | | | |
| | | CG (Sham stimulation) | | | | | | |
| | | n = 29 (sex ratio not reported) Age (years) = 61.4 ± 8.2 BMI not reported Disease duration not reported HbA1c (%) = 7.1 ± 1.5 | | | | | |
| | | VPT (Volts) = 37.6 ± 22 | | | | | |
| Grewal et al., 2013 | Observational | DPN with active DFU | Gait | 200 feet | IMU (BioSensics, Newton, MA, USA) | | Gait initiation steps | ↑ Gait initiation steps, gait speed variability in DPN groups vs. HC |
| | | n = 16 (sex ratio not reported) Age (years) = 58.3 ± 4.4 BMI (kg/m²) = 29.5 ± 3.7 Disease duration not reported Blood sugar level not reported VPT value not provided | Gait initiation distance Gait speed Stride length Gait cycle time Double stance Gait speed variability CoM sway Knee RoM | | | | |
| | | DPN without active DFU | | | | | | |
| | | n = 15 (sex ratio not reported) Age (years) = 54.2 ± 1.3 BMI (kg/m²) = 31.2 ± 5.9 Disease duration not reported Blood sugar level not reported VPT value not provided | | | | | |
| | | HC | | | | | |
| | | n = 8 (sex ratio not reported) Age (years) = 59.6 ± 6 BMI (kg/m²) = 27 ± 3.2 | | | | | |
| | | Sensor placement not reported Sampling frequency not reported | | | | | |
| Study Title | Country | Study Design | Participants | Tasks | Sensor Type (Manufacturer) | Placement Sampling Frequency | Key Measures | Findings |
|-------------|---------|--------------|--------------|-------|-----------------------------|-----------------------------|--------------|---------|
| Fear of falling is prevalent in older adults with diabetes mellitus but is unrelated to level of neuropathy | USA | Observational | DPN | n = 16 (10 men; 6 women) | Age (years) = 62 ± 2 | Gait initiation steps | IMU (BioSensics, Newton, MA, USA) | VPT (Volts) = 34.28 ± 5.9 | Gait initiation steps and double stance in DPN vs. DM without neuropathy | Gait initiation steps and double stance were significantly correlated with VPT |
| A novel shear reduction insole effect on the thermal response to walking stress, balance, and gait for diabetic neuropathy | USA | Interventional (RCT) | Immediate effect | n = 27 (14 men; 13 women) | Age (years) = 65.1 | Gait initiation steps | IMU (BioSensics, Newton, MA, USA) | VPT (Volts) = 34.28 ± 8.16 | Gait initiation steps for DFO vs. standard shoe during habitual walking |
| The influence of diabetic-peripheral neuropathy on local postural muscle and central sensory feedback balance control | USA | Observational | DPN | n = 18 (11 men; 7 women) | Age (years) = 65 ± 8 | Gait initiation steps | IMU (BioSensics, Newton, MA, USA) | VPT (mV) = 34.6 ± 7.0 | CoM sway, ankle and hip sway at 4-week vs. baseline in IG during eyes open |
| Grewal et al., 2015 [39] | USA | Sensor-based interactive balance training with visual joint movement feedback for improving postural stability in diabetics with peripheral neuropathy: A randomized controlled trial | DPN | n = 19 (male = 8, female = 11) | Age (years) = 62.58 ± 7.79 | Quiet standing | IMU (BioSensics, Newton, MA, USA) | VPT (Volts) = 34.28 ± 8.16 | CoM sway, ankle and hip sway at 4-week vs. baseline in IG during eyes open |
| Kelly et al., 2013 [37] | USA | Observational | DPN | n = 18 (5 men; 13 women) | Age (years) = 62 ± 7 | Gait | IMU (BioSensics, Newton, MA, USA) | VPT (Volts) = 49.7 ± 21.9 | Gait speed variability |
| Wrobel et al., 2014 [38] | USA | Interventional | Immediate effect | n = 18 (10 men; 6 women) | Age (years) = 69 ± 2 | Gait | IMU (BioSensics, Newton, MA, USA) | VPT (Volts) = 34.28 ± 8.16 | CoM sway, ankle and hip sway at 4-week vs. baseline in IG during eyes open |

Table 2. Cont.
Table 2. Cont.

| Study Title | Study Country | Study Design Participants | Tasks | Sensor Type (Manufacturer) | Placement | Sampling Frequency | Key Measures | Findings |
|-------------|---------------|---------------------------|-------|---------------------------|-----------|-------------------|-------------|---------|
| Teoizadeh et al., 2016 [41] | UK | Observational PAD | Gait 25 steps Two conditions | IMU (BioSensics, Newton, MA, USA) | n = 5 | Shin (n = 2; right and left) | Gait initiation steps | Gait initiation distance, and trunk sway in PAD vs. HC for both postures |
| | | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ABI (n = 2; right and left) | | | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lower back (n = 1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Frequency not reported |
| | | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thigh (n = 1; right and left) | | | | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n


| Study Title | Study Design | Participants | Tasks | Sensor Type (Manufacturer) | Placement | Sampling Frequency | Key Measures | Findings |
|-------------|--------------|--------------|-------|---------------------------|-----------|-------------------|-------------|----------|
| Kang et al., 2020 [46] | Observational | DPN | Gait 12 m | IMU (BioSensics, Newton, MA, USA) | n = 5 | Shins (n = 2; right and left) Thigh (n = 2; right and left) Lower back (n = 1) Frequency = 100 Hz Gait-initiation steps Gait-initiation distance Gait speed CoM sway | ↑ Gait-initiation steps, gait-initiation distance, and CoM sway, ↓ gait speed in DPN vs. HC for both walking |
| Characteristics of the gait initiation phase in older adults with diabetic peripheral neuropathy compared to control older adults USA | | | | | | | |
| Ling et al., 2020 [47] | Observational | DPN with DFU wearing unilateral offloading | Gait 10 m | IMU (BioSensics, Newton, MA, USA) | n = 5 | Shins (n = 2; right and left) Thigh (n = 2; right and left) Lower back (n = 1) Frequency not reported | Gait speed Stride length Gait cycle time Double support Gait-speed variability Stride-length variability Double-support limp Step-length limp | ↓ Gait speed, and stride length, ↑ gait cycle time, double-support limp, and step-length limp in DPN with DFU wearing unilateral offloading vs. DPN without DFU and HC ↑ Double support, gait-speed variability, stride-length variability in DPN with DFU wearing unilateral offloading and DPN without DFU vs. HC |
| The impact of diabetic foot ulcers and unilateral offloading footwear on gait in people with diabetes USA | | | | | | | |
| Du et al., 2021 [48] | Observational | DPN | Gait 1 min | IMU (BioSensics, Newton, MA, USA) | n = 6 | Shins (n = 2; right and left) Thigh (n = 2; right and left) Lower back (n = 1) Frequency = 100 Hz Gait speed Stride length Double support Swing phase Quiet standing: CoM sway Ankle sway Hip sway Timepoints: Baseline 1-week 1-month 4-month 6-month | ↑ Gait speed and stride length, ↓ gait cycle time, double support in offloading footwear group Quiet standing remained similar |
| The feasibility and effectiveness of wearable sensor technology in the management of elderly diabetics with foot ulcer remission: A proof-of-concept pilot study with six cases China | | | | | | | |
| Lanzi et al., 2021 [49] | Intervisional: Supervised exercise training | PAD | Gait 6 min walk task | IMU (GaitUp, Renens, Switzerland) | n = 2 | Sensor placement not specified Frequency not reported | Gait speed Stride length Stride time Stride frequency Double support Stance phase Swing phase Loading response Toe-off pitch angle Max-heel clearance First max-toe clearance Second max-toe clearance Minimum toe clearance Time points: Baseline 3-month | ↑ Gait speed, stride length, swing phase, and loading response, ↓ stance phase at 3-month vs. baseline ↑ Toe off pitch angle at 3-month vs. baseline |
| Supervised exercise training improves 6 min walking distance and modifies gait pattern during pain-free walking condition in patients with symptomatic lower extremity peripheral artery disease Switzerland | | | | | | | |

Abbreviations: DM = Diabetes mellitus; DPN = Diabetic peripheral neuropathy; DFU = Diabetic foot ulcer; BMI = Body-mass index; HC = Healthy controls; RCT = Randomized controlled trial; IG = Intervention group; CG = Control group; BMU = Inertial measurement unit; CoM = Center of mass; DFO = Dynamic foot orthoses; PAD = Peripheral artery disease; ABI = Ankle brachial index; BCW = Removable case walker; RoM = Range of motion; NA = Not available; VPT = Vibration perception threshold.
3.3. Study Design and Participant Characteristics

Of the twenty included studies, seventeen studies included people with diabetic-peripheral neuropathy, and three studies included people with peripheral-arterial disease. A total of thirteen studies were non-interventional observational studies, and seven studies were interventional studies, among which four studies were randomized controlled trials.

Among the thirteen observational studies, eight studies compared people with diabetic-peripheral neuropathy and healthy controls, among which two studies included those with active diabetic-foot ulcer; and one study compared people with peripheral-artery disease and healthy controls. Three studies included only one group of people with diabetic-peripheral neuropathy, and one study included only one group of people with recently healed diabetic-foot ulcer.

Four randomized controlled trials tested the effectiveness of exercise or electrical stimulation within groups of people with diabetic-peripheral neuropathy. Three non-randomized interventional studies tested the effectiveness of diabetic-foot orthoses and mechanical stimulation in people with diabetic-peripheral neuropathy, and the effectiveness of exercise in people with peripheral-artery disease.

For the seventeen studies which included people with diabetic-peripheral neuropathy, eleven studies reported vibration-perception threshold to measure the severity of neuropathy, and six studies reported blood sugar level. The three studies which included people with peripheral-artery disease, reported ankle-brachial index to assess lower-extremity blood flow.

3.4. Tasks and IMUs

Common tasks assessed with IMUs were gait and quiet standing in various conditions. Of the twenty studies included, twelve studies tested gait, three studies tested quiet standing, and the other five studies tested both gait and quiet standing (Figure 2).

![Figure 2. The number of papers for each task.](image)

In terms of methods, of the twenty included studies, eighteen studies used IMUs and two studies used either 3D accelerometers or gyroscopes (Figure 3). The number of sensors was between one and five. Sampling frequencies, if reported, were either 100 Hz or 200 Hz. Common sensor positions for gait assessment were the lower back, thighs, and shins for the five-sensor system; the thighs and shins for the four-sensor system; the shins for the two-sensor system; and the lower back for the one-sensor system. One study that used 3D accelerometers for gait assessment attached the sensors to the head and lower back. For assessing balance during quiet standing, two IMUs were commonly used with the sensors attached to the lower back and shin.
In terms of quiet standing, center-of-mass sway was the most popular measure, which was reported in 100% of quiet-standing studies (Figure 5). Other variables of quiet standing included ankle sway and hip sway. There was one study which reported local-control balance and central-control balance.

3.5. Measures and Key Findings

The most popular gait measures were gait speed, stride length (or step length), and stride time (or gait cycle time or step time), each of which was reported in 100% of gait studies (Figure 4). Gait-variability measures (i.e., fluctuations in stride-to-stride), such as gait-speed variability, stride-time variability, and stride-length variability were reported in ten studies. Gait-initiation variables, including the number of steps and distance to be taken from standing posture to steady state walking, were reported in six studies. There was one study which quantified smoothness using the harmonic ratio, and another study quantified limping during gait. Besides, one study reported foot-kinematic variables, such as toe clearance.

Figure 3. The number of papers for each sensor type.

Figure 4. The number of papers for each gait variable.
In terms of key findings, gait studies reported slow gait speed, shorter stride length, greater gait variability, and longer gait-initiation phase in people with diabetic foot, compared to control subjects (e.g., healthy controls, people with diabetes but no diabetic foot). Similarly, studies that measured quiet standing reported larger sway in center-of-mass, ankle, or hip in people with diabetic foot, compared to control subjects. Interventional studies also reported improvements in these gait and quiet-standing measures at post-intervention, compared to pre-intervention.

4. Discussion

4.1. Summary

We aimed to provide an up-to-date review of the existing literature regarding assessment of gait and balance using wearable IMUs in people with diabetic foot. Given the main role of the foot during gait (i.e., force absorption) and biomechanical deformities in diabetic foot, the importance of assessing gait and balance has been continuously emphasized in numerous review papers [14,15,50,51]. Furthermore, gait and balance dysfunction is the key indicator of increased risk of falling in people with diabetic foot, which might in turn increase risk of hospitalization [52,53]. Gait and balance dysfunction may facilitate ulceration because of abnormal loading pattern [54].

In this mini review, we identified a total of 20 papers that met our inclusion and exclusion criteria. Although there were some heterogeneities in gait and quiet-standing protocols and findings, across the reviewed studies, key parameters of IMU-based gait and balance assessment were gait speed, gait-initiation steps and distance, gait variability, and body sway during quiet standing. Furthermore, reviewed studies demonstrated reasonably consistent patterns of such parameters in people with diabetic foot in comparison to non-diabetic people or in response to an intervention.

Based on these findings, our mini review suggests IMUs may have potential to be used in clinical settings to measure kinematic aspects of gait and balance dysfunction in people with diabetic-peripheral neuropathy, active diabetic-foot ulcer, or peripheral-artery disease. Furthermore, IMU-based parameters could assist in designing remote-patient-monitoring platform to track changes in digital biomarkers of gait and balance dysfunction among people with diabetic foot. To our knowledge, this is the first review (regardless of the type of the review) that focused on gait and balance assessment using IMUs in people with diabetic foot. Our review may also be used as the first step towards establishing a general agreement on gait metrics specifically described for people with diabetic foot.

4.2. Challenges and Future Directions

From this review, we realized an agreed protocol for IMU-based gait assessment is urgently needed. Although most of the studies that tested IMU-based quiet standing
used similar protocols adopted from the Romberg test [55], protocols for gait assessment varied significantly between studies in terms of distance, single or dual task conditions, speed conditions, and footwear conditions. These varied conditions might have resulted in heterogeneities in gait results. Furthermore, IMU-based gait outcomes that can indicate an important sub-phase of gait cycle, such as propulsion phase or breaking phase, would be beneficial. Because these phases account for the greatest shear and vertical pressure on the foot during gait, which is directly associated with an onset of an ulcer (i.e., skin breakdown) or progressing ulcerations, a way to assess characteristics of these phases will be particularly beneficial for people with diabetic foot.

Another important issue is the repeatability. Repeatability of IMU-based, gait analysis and balance assessment has been reported in general or other clinical populations [56,57]. For example, Washabaugh and colleagues used commercially available IMUs (APDM Inc., Portland, OR; n = 2), attached on the feet or ankles, and evaluated repeatability of the IMUs in measuring spatiotemporal-gait parameters during overground gait (three trials; healthy young adults), including gait speed, stride length, and cadence [56]. They reported high repeatability of the IMU-based, spatiotemporal-gait parameters. Felius and colleagues used a commercially available IMU (Aemics b.v. Olden-zaal, The Netherlands) and evaluated repeatability of the IMUs in measuring balance parameters of the trunk in quiet standing [57]. They reported medium-to-high repeatability of the IMU-based balance parameters. However, we were unable to find evidence of repeatability in people with diabetic foot. It is urgently needed to investigate if IMUs can provide repeatable gait or balance parameters in diabetic foot.

Small sample sizes in nearly every included study is another issue. Surprisingly, regardless of study design, the maximum number of participants in a group (either intervention group or control group in a randomized controlled trial) was 38. These two issues can lead to a subsequent question of the generalizability of the findings. In terms of participant characteristics included in this review, the vast majority of the recruited people had diabetic-peripheral neuropathy, the most common underlying etiology causing a diabetic foot ulcer [58], but reports are needed for different diabetic-foot problems, such as Charcot foot and diabetic foot in remission [59,60].

Limitations of this review should be acknowledged. Due to the issues regarding study protocol, repeatability, and small sample size, we recommend considering our review as a preliminary review, not a confirmatory work. Another limitation is heterogeneity in IMUs. Although validations of the IMUs that were chosen in each paper have been reported previously, different IMUs may have slightly different results for sampling frequency and filtering techniques, though this has not been reported in the included papers.

Despite these limitations, based on the current status of using IMUs in assessing gait and balance in the management of diabetic foot, we believe the following examples are areas of future research. One primary area is to establish an implementation strategy. One strength of IMUs is the possibility of them being incorporated into clinical practice. IMUs provide more detailed and necessary information about a person’s functional status comparable to a stopwatch, and are more portable and translational, compared to three-dimensional, optoelectronic-motion-capture technology. In fact, the importance of implementation has been discussed previously [27,61], and implementation has been attempted in another population [62]. We believe appropriate strategies, such as IMU-based, perioperative-gait assessment will significantly advance the management of diabetic foot. Another primary area is to better identify people at the highest risk of diabetic-foot ulceration. This may be particularly beneficial for those who have recently recovered from a diabetic-foot ulcer. IMU-based gait assessment during clinic visits on a regular basis (e.g., every three or six months according to established guidelines) may better identify those whose ulcers are likely to recur and those who will likely remain ulcer-free.
5. Conclusions

Assessing gait and balance dysfunction and investigating biomechanics have undoubtedly advanced our understanding of diabetic-foot syndrome. Based on our review, we found that IMU-based gait and balance assessment can provide information regarding gait analysis, gait initiation, and gait variability, and body sway during quiet standing. Our review identified several issues and limitations of the included studies, and suggested future directions that may address current limitations and achieve advancements in diabetic-foot management. We believe rapid developments in sensing technology and data-analysis technology will further speed up the processes to successfully incorporate IMUs into clinical practice.

Author Contributions: Conceptualization, G.E.K. and L.A.L.; methodology, G.E.K., A.S., K.W. and S.K.; writing—original draft preparation, G.E.K.; writing—review and editing, G.E.K., A.S., K.W., S.K., A.L.K., P.A.C., M.S., D.J., B.N., A.V. and L.A.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Shirley Ryan AbilityLab C-STAR Collaborative Mentorship Funding; grant number P2C HD101899.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No data were generated.

Conflicts of Interest: G.E.K., A.S., K.W., S.K., A.L.K., P.A.C., M.S., D.J. and L.A.L. declare no conflict of interest. B.N. and A.V. are a consultant, a founder, and the CEO of BioSensics LLC, respectively, which is a manufacturer of one of the IMUs referenced in this review; however, they were not involved in the selection of papers and their contributions were limited to technical discussion, interpretation of the results, and reviewing and editing of the manuscript. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. Herman, W.H. The global burden of diabetes: An overview. In Diabetes Mellitus in Developing Countries and Underserved Communities; Springer: Berlin/Heidelberg, Germany, 2017; pp. 1–5.
2. Sun, H.; Saeedi, P.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B.B.; Stein, C.; Basit, A.; Chan, J.C.; Mbanya, J.C. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022, 183, 109119. [CrossRef] [PubMed]
3. Association, A.D. Economic costs of diabetes in the US in 2017. Diabetes Care 2018, 41, 917–928. [CrossRef]
4. Alberti, K.G.M.M.; Zimmet, P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 1998, 15, 539–553. [CrossRef]
5. Atkinson, M.A.; Eisenbarth, G.S.; Michels, A.W. Type 1 diabetes. Lancet 2014, 383, 69–82. [CrossRef] [PubMed]
6. Chatterjee, S.; Khunti, K.; Davies, M.J. Type 2 diabetes. Lancet 2017, 389, 2239–2251. [CrossRef] [PubMed]
7. van Netten, J.J.; Bus, S.A.; Apelqvist, J.; Lipsky, B.A.; Hinchcliffe, R.J.; Game, F.; Rayman, G.; Lazzarini, P.A.; Forsythe, R.O.; Peters, E.J. Definitions and criteria for diabetic foot disease. Diabetes/Metab. Res. Rev. 2020, 36, e3268. [CrossRef] [PubMed]
8. Armstrong, D.G.; Boulton, A.J.; Bus, S.A. Diabetic foot ulcers and their recurrence. N. Engl. J. Med. 2017, 376, 2367–2375. [CrossRef] [PubMed]
9. Boulton, A.J.; Armstrong, D.G.; Kirsner, R.S.; Attinger, C.E.; Lavery, L.A.; Lipsky, B.A.; Mills, J.L.; Steinberg, J.S. Diagnosis and management of diabetic foot complications. Compendia 2018, 2018. [CrossRef]
10. Bakker, K.; Schaper, N.C.; on behalf of the International Working Group on the Diabetic Foot Editorial Board. The development of global consensus guidelines on the management and prevention of the diabetic foot 2011. Diabetes/Metab. Res. Rev. 2012, 28, 116–118. [CrossRef] [PubMed]
11. Geiss, L.S.; Li, Y.; Hora, I.; Albright, A.; Rolka, D.; Gregg, E.W. Resurgence of diabetes-related nontraumatic lower-extremity amputation in the young and middle-aged adult US population. Diabetes Care 2019, 42, 50–54. [CrossRef] [PubMed]
12. Wukich, D.K.; Raspovic, K.M.; Suder, N.C. Patients with diabetic foot disease fear major lower-extremity amputation more than death. Foot Ankle Spec. 2018, 11, 17–21. [CrossRef]
13. Lavery, L.A.; Grigopoulos, K.; Killeen, A.L.; La Fontaine, J. Elective Surgery in the Diabetic Foot to Heal Foot Ulcerations and Prevent Re-ulceration. In Diabetic Foot Reconstruction; Springer: Berlin/Heidelberg, Germany, 2022; pp. 53–76.
14. Wrobel, J.S.; Najafi, B. Diabetic foot biomechanics and gait dysfunction. J. Diabetes Sci. Technol. 2010, 4, 833–845. [CrossRef] [PubMed]

15. Alam, U.; Riley, D.R.; Jugdev, R.S.; Azmi, S.; Rajbhandari, S.; D’Aout, K.; Malik, R.A. Diabetic neuropathy and gait: A review. Diabetes Ther. 2017, 8, 1253–1264. [CrossRef] [PubMed]

16. Cavanagh, P.; Derr, J.; Ulbrecht, J.; Maser, R.; Orchard, T. Problems with gait and posture in neuropathic patients with insulin—Dependent diabetes mellitus. Diabet. Med. 1992, 9, 469–474. [CrossRef]

17. Allet, L.; Armand, S.; De Bie, R.; Golay, A.; Pataky, Z.; Aminian, K.; De Bruin, E.D. Clinical factors associated with gait alterations in diabetic patients. Diabet. Med. 2009, 26, 1003–1009. [CrossRef] [PubMed]

18. Kang, G.E.; Najafi, B. Sensor-based daily physical activity: Towards prediction of the level of concern about falling in peripheral neuropathy. Sensors 2020, 20, 505. [CrossRef] [PubMed]

19. Kang, G.E.; Murphy, T.K.; Kunik, M.E.; Badr, H.J.; Workeneh, B.T.; Yellapragada, S.V.; Sada, Y.H.; Najafi, B. The detrimental association between fear of falling and motor performance in older cancer patients with chemotherapy-induced peripheral neuropathy. Gait Posture 2021, 88, 161–166. [CrossRef] [PubMed]

20. Sawacha, Z.; Guarneri, G.; Cristoferi, G.; Guiotto, A.; Avogaro, A.; Cobelli, C. Integrated kinematics-kinetics-plantar pressure data analysis: A useful tool for characterizing diabetic foot biomechanics. Gait Posture 2012, 36, 20–26. [CrossRef]

21. Lazzarini, P.A.; Crews, R.T.; van Netten, J.J.; Bus, S.A.; Fernando, M.E.; Chadwick, P.J.; Najafi, B. Measuring plantar tissue stress in people with diabetic peripheral neuropathy: A critical concept in diabetic foot management. J. Diabetes Sci. Technol. 2019, 13, 869–880. [CrossRef] [PubMed]

22. Myers, M. Qualitative research and the generalizability question: Standing firm with Proteus. Qual. Rep. 2000, 4, 9. [CrossRef] [PubMed]

23. Gordt, K.; Gerhardy, T.; Najafi, B.; Schwenk, M. Effects of wearable sensor-based balance and gait training on balance, gait, and functional performance in healthy and patient populations: A systematic review and meta-analysis of randomized controlled trials. Gerontology 2018, 64, 74–89. [CrossRef] [PubMed]

24. Myres, R.F.; Naughton, G.A.; Silburn, P.A.; Cole, M.H. Wearable sensor use for assessing standing balance and walking stability in people with Parkinson’s disease: A systematic review. PLoS ONE 2015, 10, e0123705. [CrossRef] [PubMed]

25. Hubble, R.P.; Naughton, G.A.; Silburn, P.A.; Cole, M.H. Wearable sensor use for assessing standing balance and walking stability in people with Parkinson’s disease: A systematic review. PLoS ONE 2015, 10, e0123705. [CrossRef] [PubMed]

26. Schwenk, M.; Mohler, J.; Wendel, C.; Fain, M.; Taylor-Piliae, R.; Najafi, B. Wearable sensor-based in-home assessment of gait, balance, and physical activity for discrimination of frailty status: Baseline results of the Arizona frailty cohort study. Gerontology 2015, 61, 258–267. [CrossRef] [PubMed]

27. Najafi, B.; Reeves, N.D.; Armstrong, D.G. Leveraging smart technologies to improve the management of diabetic foot ulcers and extend ulcer-free days in remission. Diabetes/Metab. Res. Rev. 2020, 36, e3239. [CrossRef] [PubMed]

28. Kang, G.E.; Patriquin, M.A.; Nguyen, H.; Oh, H.; Rufino, K.A.; Storch, E.A.; Schanzer, B.; Mathew, S.J.; Salas, R.; Najafi, B. Objective measurement of sleep, heart rate, heart rate variability, and physical activity in suicidality: A systematic review. J. Affect. Disord. 2020, 273, 318–327. [CrossRef] [PubMed]

29. Kang, G.E.; Frederick, R.; Nunley, B.; Lavery, L.; Daher, Y.; Najafi, B.; Cogan, S. The effect of implanted functional electrical stimulation on gait performance in stroke survivors: A systematic review. Sensors 2021, 21, 8323. [CrossRef]

30. Menz, H.B.; Lord, S.R.; St George, R.; Fitzpatrick, R.C. Walking stability and sensorimotor function in older people with diabetic peripheral neuropathy. Arch. Phys. Med. Rehabil. 2004, 85, 245–252. [CrossRef] [PubMed]

31. Allet, L.; Armand, S.; De Bie, R.A.; Pataky, Z.; Aminian, K.; Herrmann, F.R.; de Bruin, E.D. Gait alterations of diabetic patients while walking on different surfaces. Gait Posture 2009, 29, 488–493. [CrossRef] [PubMed]

32. Allet, L.; Armand, S.; Aminian, K.; Pataky, Z.; Golay, A.; De Bie, R.; de Bruin, E.D. An exercise intervention to improve diabetic patients’ gait in a real-life environment. Gait Posture 2010, 32, 185–190. [CrossRef] [PubMed]

33. Crews, R.T.; Sayeed, F.; Najafi, B. Impact of strut height on offloading capacity of removable cast walkers. Clin. Biomech. 2012, 27, 725–730. [CrossRef] [PubMed]

34. Najafi, B.; Khan, T.; Fleischer, A.; Wrobel, J. The impact of footwear and walking distance on gait stability in diabetic patients with peripheral neuropathy. J. Am. Podiatr. Med. Assoc. 2013, 103, 165–173. [PubMed]

35. Crews, R.T.; Wrobel, J.S. A novel plantar stimulation technology for improving protective sensation and postural control in patients with diabetic peripheral neuropathy: A double-blinded, randomized study. Gerontology 2013, 59, 473–480. [CrossRef] [PubMed]

36. Grewal, G.S.; Bharara, M.; Menzies, R.; Talal, T.K.; Armstrong, D.; Najafi, B. Diabetic peripheral neuropathy and gait: Does footwear modify this association? J. Diabetes Sci. Technol. 2013, 7, 1138–1146. [CrossRef] [PubMed]

37. Kelly, C.; Fleischer, A.; Yalla, S.; Grewal, G.S.; Albright, R.; Berns, D.; Crews, R.; Najafi, B. Fear of falling is prevalent in older adults with diabetes mellitus but is unrelated to level of neuropathy. J. Am. Podiatr. Med. Assoc. 2013, 103, 480. [CrossRef] [PubMed]

38. Wrobel, J.S.; Ammanath, P.; Le, T.; Luring, C.; Wensman, J.; Grewal, G.S.; Najafi, B.; Pop-Busui, R. A novel shear reduction insole effect on the thermal response to walking stress, balance, and gait. J. Diabetes Sci. Technol. 2014, 8, 1151–1156. [CrossRef] [PubMed]

39. Najafi, B.; Crews, R.T.; Wrobel, J.S. A novel plantar stimulation technology for improving protective sensation and postural control in patients with diabetic peripheral neuropathy: A double-blinded, randomized study. Gerontology 2013, 59, 473–480. [CrossRef] [PubMed]

40. Grewal, G.S.; Bharara, M.; Menzies, R.; Talal, T.K.; Armstrong, D.; Najafi, B. Diabetic peripheral neuropathy and gait: Does footwear modify this association? J. Diabetes Sci. Technol. 2013, 7, 1138–1146. [CrossRef] [PubMed]

41. Kelly, C.; Fleischer, A.; Yalla, S.; Grewal, G.S.; Albright, R.; Berns, D.; Crews, R.; Najafi, B. Fear of falling is prevalent in older adults with diabetes mellitus but is unrelated to level of neuropathy. J. Am. Podiatr. Med. Assoc. 2013, 103, 480. [CrossRef] [PubMed]

42. Wrobel, J.S.; Ammanath, P.; Le, T.; Luring, C.; Wensman, J.; Grewal, G.S.; Najafi, B.; Pop-Busui, R. A novel shear reduction insole effect on the thermal response to walking stress, balance, and gait. J. Diabetes Sci. Technol. 2014, 8, 1151–1156. [CrossRef] [PubMed]
39. Grewal, G.S.; Schwenk, M.; Lee-Eng, J.; Parvaneh, S.; Bharara, M.; Menzies, R.A.; Talal, T.K.; Armstrong, D.G.; Najafi, B. Sensor-based interactive balance training with visual joint movement feedback for improving postural stability in diabetics with peripheral neuropathy: A randomized controlled trial. *Gerontology* 2015, 61, 567–574. [CrossRef]

40. Toosizadeh, N.; Mohler, J.; Armstrong, D.G.; Talal, T.K.; Najafi, B. The influence of diabetic peripheral neuropathy on local postural muscle and central sensory feedback balance control. *PLoS ONE* 2015, 10, e0135255. [CrossRef] [PubMed]

41. Toosizadeh, N.; Stocker, H.; Thiede, R.; Mohler, J.; Mills, J.L.; Najafi, B. Alterations in gait parameters with peripheral artery disease: The importance of pre-frailty as a confounding variable. *Vasc. Med.* 2016, 21, 520–527. [CrossRef] [PubMed]

42. Thiede, R.; Toosizadeh, N.; Mills, J.L.; Zaky, M.; Mohler, J.; Najafi, B. Gait and balance assessments as early indicators of frailty in patients with known peripheral artery disease. *Clin. Biomch.* 2016, 32, 1–7. [CrossRef] [PubMed]

43. Najafi, B.; Talal, T.K.; Grewal, G.S.; Menzies, R.; Armstrong, D.G.; Lavery, L.A. Using plantar electrical stimulation to improve postural balance and plantar sensation among patients with diabetic peripheral neuropathy: A randomized double blind study. *J. Diabetes Sci. Technol.* 2017, 11, 693–701. [CrossRef]

44. Esser, P.; Collett, J.; Maynard, K.; Steins, D.; Hillier, A.; Buckingham, J.; Tan, G.D.; King, L.; Dawes, H. Single sensor gait analysis to detect diabetic peripheral neuropathy: A proof of principle study. *Diabetes Metab. J.* 2018, 42, 82–86. [CrossRef] [PubMed]

45. Kang, G.E.; Zahiri, M.; Lepow, B.; Saleem, N.; Najafi, B. The effect of daily use of plantar mechanical stimulation through micro-mobile foot compression device installed in shoe insoles on vibration perception, gait, and balance in people with diabetic peripheral neuropathy. *J. Diabetes Sci. Technol.* 2019, 13, 847–856. [CrossRef]

46. Kang, G.E.; Zhou, H.; Varghese, V.; Najafi, B. Characteristics of the gait initiation phase in older adults with diabetic peripheral neuropathy compared to control older adults. *Clin. Biomech.* 2020, 72, 155–160. [CrossRef] [PubMed]

47. Ling, E.; Lepow, B.; Zhou, H.; Enriquez, A.; Mullen, A.; Najafi, B. The impact of diabetic foot ulcers and unilateral offloading footwear on gait in people with diabetes. *Clin. Biomech.* 2020, 73, 157–161. [CrossRef] [PubMed]

48. Du, C.; Wang, H.; Chen, H.; Fan, X.; Liu, D.; Du, D.; Wu, M.; Wang, G.; Boey, J.; Armstrong, D.G. The feasibility and effectiveness of wearable sensor technology in the management of elderly diabetics with foot ulcer remission: A proof-of-concept pilot study with six cases. *Gerontology* 2021, 67, 493–502. [CrossRef]

49. Lanzi, S.; Boichat, J.; Calanca, L.; Mazzolai, L.; Malatesta, D. Supervised Exercise Training Improves 6 min Walking Distance and Modifies Gait Pattern during Pain-Free Walking Condition in Patients with Symptomatic Lower Extremity Peripheral Artery Disease. *Sensors* 2021, 21, 7989. [CrossRef]

50. Kirby, K. Biomechanics of the normal and abnormal foot. *J. Am. Podiatr. Med. Assoc.* 2000, 90, 30–34. [CrossRef]

51. Van Schie, C.M. A review of the biomechanics of the diabetic foot. *Int. J. Low. Extrem. Wounds* 2005, 4, 160–170. [CrossRef]

52. Khan, K.S.; Andersen, H. The impact of diabetic neuropathy on activities of daily living, postural balance and risk of falls—A systematic review. *J. Diabetes Sci. Technol.* 2022, 16, 289–294. [CrossRef] [PubMed]

53. Yau, R.K.; Strotmeyer, E.S.; Resnick, H.E.; Sellmeyer, D.E.; Feingold, K.R.; Cauley, J.A.; Vittinghoff, E.; De Rekeneire, N.; Harris, T.B.; Nevitt, M.C. Diabetes and risk of hospitalized fall injury among older adults. *Diabetes Care* 2013, 36, 3985–3991. [CrossRef]

54. Lavery, L.A.; Armstrong, D.G.; Wunderlich, R.P.; Tredwell, J.; Boulton, A.J. Predictive value of foot pressure assessment as part of a population-based diabetes disease management program. *Diabetes Care* 2003, 26, 1069–1073. [CrossRef]

55. Black, F.O.; Wall, C., III; Rockette, H.E., Jr.; Kitch, R. Normal subject postural sway during the Romberg test. *Am. J. Otolaryngol.* 1982, 3, 309–318. [CrossRef] [PubMed]

56. Washabaugh, E.P.; Kalyanaraman, T.; Adamczyk, P.G.; Claflin, E.S.; Krishnan, C. Validity and repeatability of inertial measurement units for measuring gait parameters. *Gait Posture* 2017, 55, 87–93. [CrossRef] [PubMed]

57. Felius, R.; Geerars, M.; Bruijn, S.; Wouda, N.; Van Deew, J.; Punt, M. Reliability of IMU-Based Balance Assessment in Clinical Stroke Rehabilitation. *Gait Posture* 2022, 98, 62–68. [CrossRef]

58. Thiede, R.; Toosizadeh, N.; Mills, J.L.; Zaky, M.; Mohler, J.; Najafi, B. Altered gait and balance assessments as early indicators of frailty in patients with known peripheral artery disease. *Clin. Biomch.* 2016, 32, 1–7. [CrossRef] [PubMed]

59. La Fontaine, J.; Lavery, L.; Jude, E. Current concepts of Charcot foot in diabetic patients. *Foot* 2016, 26, 7–14. [CrossRef]

60. Petersen, B.J.; Bus, S.A.; Rothenberg, G.M.; Linders, D.R.; Lavery, L.A.; Armstrong, D.G. Recurrence rates suggest delayed identification of plantar ulceration for patients in diabetic foot remission. *BMJ Open Diabetes Res. Care* 2020, 8, e001697. [CrossRef]

61. Bus, S.A.; van Netten, J.J.; Monteiro-Soares, M.; Lipsky, B.A.; Schaper, N.C. Diabetic foot disease: “The Times They Are A Changin’." *Diabetes/Metab. Res. Rev.* 2020, 36, e3249. [CrossRef]

62. Jayaram, P.; Kang, G.E.; Heldt, B.L.; Sokumbi, O.; Song, B.; Yeh, P.C.; Epstein, M.; Shybut, T.B.; Lee, B.H.; Najafi, B. Novel assessment of leukocyte-rich platelet-rich plasma on functional and patient-reported outcomes in knee osteoarthritis: A pilot study. *Regen. Med.* 2021, 16, 823–832. [CrossRef]